Singapore Lyophilization Equipment Industry Overview:
Lyophilization equipment or lyophilizer execute dehydration process that
is essential to preserve perishables and make materials more convenient for
storage or transport. The equipment works by freezing the materials and
reducing the surround to allow the ice to sublimate. In pharmaceutical industries,
the process is used to increase the shelf-life of antibiotics, protein-based
drugs, and vaccines. The largest end-use industry of lyophilization equipment is
biopharmaceutical companies that use the equipment to keep APIs and drugs
sterile. Thus, the focus toward improving manufacturing practices has
increased.
According to Allied Market Research, the global Singapore lyophilization equipment
market is expected to
reach $10.61 billion by 2030, growing at a CAGR of 7.8% from 2021 to 2030. Rise
in demand for lyophilized products and preserved food, technological
advancements in lyophilization equipment, and surge in production of
protein-based drugs, biopharmaceuticals, and injectables have boosted the
growth of the market growth.
Impact of COVID-19 Pandemic on Singapore Lyophilization Equipment Market (Pre & Post Analysis)
However, in 2020, the outbreak of the COVID-19 pandemic led to have a
negative impact on the growth of the lyophilization equipment market,
especially in the initial period. The implementation of global lockdown
restricted the functioning hours of all endoscopy procedures across the world.
In order to maintain the social distancing norms, most of the departments in
the hospitals were closed and few of them were opened with limited staff.
Nevertheless, the global lyophilization equipment market is going to get back
on track with a steady pace, once the lockdown is completely over.
Request for Sample Report for
More Insights@ https://www.alliedmarketresearch.com/request-sample/11580
Top Leading Players:
·
Thermo
Fisher Scientific
·
Azbil
Telstar SL (Azbil Corporation)
·
GEA Group
·
Millrock
Technology
·
Zirbus
Technology GmbH
·
Harbour
Group Industries (SP Industries)
Recently, SP Scientific Products (SP) launched its SP Hull LyoStar 4.0.
The process development freezer dryer is developed to improve the speed to
market of biopharmaceutical products including biological drugs. The new device
is a result of advancements in freeze dryer engineering and offers superior
shelf mapping, unmatched process accuracy and reliability, and rapid shelf
freezing. Moreover, it offers cutting-edge suite process analytical technology
(PAT) tools. This lyophilization equipment uses eco-friendlier refrigerant gas
and helps in reducing the carbon footprint that is commonly involved in
lyophilization.
As lyophilization is a vital step in the production of biologics,
diagnostics, and vaccines, more and more companies have entered the market and
invested heavily in R&D to improve the existing lyophilization equipment.
Stabilizing sensitive biological products while maintaining efficacy and
quality is one of the prime challenges while designing lyophilization equipment.
Thus, companies need to invest in developing more advanced, reliable, scalable
lyophilization equipment and lyophilization technologies to support drug
development and manufacturing.
With the introduction of new ways of freeze-drying, there are new
opportunities on the horizon. For instance, active freeze-drying can be used
for a few liters for small-scale and lab-scale production applications as well
as bulk drying of hundreds of liters. This way of lyophilization offers rapid
drying which is essential for freezing materials for customers in various
fields. In fact, the materials from regular insects to pharmaceuticals and
exclusive herbs, such new ways of lyophilization have opened new opportunities.
Moreover, while PAT tools and quality by design (QbD) are leading the market,
the design of lyophilization equipment would soon become the prime focus of the
pharmaceutical industry.
.jpeg)
0 Comments